Estrella Immunopharma, Inc. (ESLA) vs Neuphoria Therapeutics Inc. (NEUP)
A side-by-side comparison of Estrella Immunopharma, Inc. and Neuphoria Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ESLA
Estrella Immunopharma, Inc.
$0.47HealthcareDelayed quote: Oct 6, 2026, 11:08 AM EDT
NEUP
Neuphoria Therapeutics Inc.
$3.50HealthcareDelayed quote: Oct 6, 2026, 11:08 AM EDT
Total return — ESLA vs NEUP
growth of $100 · dividends reinvested · last 5yESLA -95.5% (-46.3%/yr)NEUP -98.0% (-54.5%/yr)ESLA compounded faster over this window
ESLA NEUP
ESLA vs NEUP: by the numbers
- •ESLA is the larger company ($20M vs $19M market cap).
- •Both run net losses; ESLA's is the smaller (0.00% vs -1578.40% net margin).
Metrics side by side
Valuation
| Metric | ESLA | NEUP |
|---|---|---|
| P/S ratio | N/A | 16.11 |
| P/B ratio | N/A | 0.77 |
Profitability
| Metric | ESLA | NEUP |
|---|---|---|
| Gross margin | 0.00% | 43.54% |
| Operating margin | 0.00% | -835.53% |
| Net margin | 0.00% | -1578.40% |
| ROE | N/A | -75.34% |
| ROIC | N/A | -49.83% |
Growth (annualized)
| Metric | ESLA | NEUP |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 11.12% |
| Total return CAGR (5Y) | -46.34% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.